VectraCor Cuts to the Heart of Cardiac Symptoms
According to the American Heart Association, approximately 325,000 people per year die of a heart attack before they can reach a hospital.
heart attack
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
PAD Awareness Month Brings Often-Overlooked Cardiovascular Disease to the Forefront
While most people are familiar with the big-name heart problems such as cardiac arrest and congestive heart failure, PAD is often overlooked.
Giving the Cold Shoulder to Cardiac Arrest Complications
According to a recent Reuters article, a treatment known as therapeutic hypothermia is saving the lives of cardiac arrest patients in hospitals across the U.S.
Growing Regenerative Medicine Market Provides Opportunities for Cytori Therapeutics
For many breast cancer patients, the effects of undergoing a mastectomy go well beyond the physical.
[Company Profile] Stentys
Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.
Cytori’s Cardiac Celution: Encouraging Interim Data
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.
Wireless Pacemakers Approved for Patient Use
With the U.S. approval of two new wireless devices from St. Jude Medical, pacemaker users may no longer have to go to the doctor for follow-up visits.
AstraZeneca’s Heart Drug Beats Plavix in Phase III Study
Blood-thinning drug Plavix racks up over $8 billion in annual sales, but the blockbuster medication may have some new competition.
Good News for Market-Leading Stent
A new study by Abbott Laboratories found that their drug-coated stent, Xience V, is more effective in the long term than a competitor’s. According to the Wall Street Journal, the data showed that rates of major cardiovascular events plateaued at 6.4% in the second and third years after Xience was implanted.